To evaluate the safety and tolerability of belimumab given for 24 months in patients persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable to aPL [refractory and/or non-criteria manifestations of the antiphospholipid syndrome (APS)].
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of antiphospholipid syndrome: study protocol
Sciascia, Savino
Co-first
;Radin, MassimoCo-first
;Cecchi, Irene;Barinotti, Alice;Rubini, Elena;Rossi, Daniela;Fenoglio, Roberta;Menegatti, Elisa;Roccatello, DarioLast
2023-01-01
Abstract
To evaluate the safety and tolerability of belimumab given for 24 months in patients persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable to aPL [refractory and/or non-criteria manifestations of the antiphospholipid syndrome (APS)].
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory andor non-criter.pdf
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
313.58 kB
Formato
Adobe PDF
|
313.58 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
